The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry.

Thorn GJ[1†], Gadaleta E[1†], Abdollahyan M[1], Dayem Ullah, AZM[1], Barrow-McGee, R[2], Jones, JL[2], Chelala C[1*]

[1]Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK
[2]Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK

* To whom correspondence should be addressed. Claude Chelala, Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. Email: c.chelala@qmul.ac.uk

[†]The first 2 authors should be regarded as joint First Authors.

ABSTRACT

Breast cancer is the most commonly diagnosed cancer globally and the leading cause of cancer death in women, with ethnic disparities reported in cancer incidence, prognosis, diagnosis and therapeutic response. Although precision oncology holds the promise of revolutionising healthcare, it could exacerbate the racial disparities it seeks to eradicate unless rigorous efforts are made to address research biases.

We evaluated the molecular and clinical effects of genetic ancestry in African and South Asian women using a combined cohort of 7,136 breast cancer patients available from four data sources – the 100,000 Genomes Project (UK), The Cancer Genome Atlas (US), the Breast Cancer Now Biobank (London, UK) and Genes & Health (UK).

Using patients assigned to the European genetic ancestry as the baseline comparator for all analyses, we find that non-European patients present with breast cancer significantly earlier and die at a younger age. Patients within the African group also have an increased prevalence of higher grade and hormone receptor negative disease. South Asian patients show a small tendency towards lower stage at diagnosis, and a lower tumour mutational burden.

We observed significant differences and similarities in the somatic mutational landscape of the non-European populations. Six genes, *RBM5*, *OTOF*, *FBXW7*, *NCKAP5*, *NOTCH3* and

GPR158, were differentially mutated across multiple cohorts. Furthermore, potential therapeutic candidates (*BRIP1, CDKN2A, CHEK2, FBXW7*, *GPR158, KDM6A, RET, STK11*) were found to be differentially mutated across the African and/or South Asian genetic ancestry groups. Genes with significant differences in germline mutation rates were identified in African and South Asian populations, including those used in current genetic testing (African: *TP53*, *BRCA1*, *BRCA2*, *PALB2*, $p<0.001$; South Asian: *TP53*, *BRCA1*, *BRCA2*, $p<0.05$) as well as those implicated in breast cancer predisposition in the literature, such as *CDH1*, *CDK2A*, *ERCC3*, *EPCAM*, *FANCA*, *FANCC, POLE* and *PMS2*. There is a higher propensity for BRCAness in the African population, with a lower rate in the South Asian population, serving as a potential prognostic indicator into the response to therapies such as PARP inhibitors.

Our study confirms the under-representation of non-European ethnic minority groups within research studies, clinical applications and biobanks, with none of the resources able to recapitulate the ethnic diversity of their representative geographical locations (UK, London and US). Finally, our findings advocate for the implementation of ancestry-specific germline mutation breast cancer screening windows and germline screening panels.

This study harnesses multimodal data to improve our understanding of ancestry-associated differences in breast cancer and highlight opportunities to advance health equity in breast cancer thus taking one step closer to achieving the promise of equitable precision oncology.

INTRODUCTION

Breast cancer (BC) is the most commonly diagnosed cancer globally and the leading cause of cancer death in women, with an estimated 2.3 million new cases annually and accounting for about 685,000 deaths in 2020.[1] Racial disparities are observed in these figures, with higher mortality rates reported in ethnic minority populations. While social determinants of health have been shown to contribute to population-based differences in mortality, they do not fully explain the disparity observed.[2]

Precision oncology is transforming the landscape of healthcare by offering a future in which the one-size-fits-all approach is superseded by tailored diagnosis and treatment. However, the under-representation of patients from ethnic minority populations in research studies and clinical trials limits the impact of translating these findings to non-white patients, exacerbating racial gaps in care delivery.[3,4] Observed disparities in outcomes between ethnic groups are likely perpetuated by differences in the distributions of germline pathogenic variants, the incidence of different subtypes, unique somatic mutations, pharmacokinetic behaviour, and tumour biology and behaviour.[5-11] Additionally, reports have shown that disease risk models and polygenic risk scores used for disease stratification can exhibit lower predictive accuracy in non-white populations.[11-17]

To improve our understanding of how the range of genomic and clinical features contribute to breast cancer in different ethnic groups, we analysed data from four large-scale UK and US projects – Genomics England 100,000 Genomes Project[18], The Cancer Genome Atlas (TCGA)[19], the Breast Cancer Now Biobank (BCN Biobank)[20] and Genes & Health (G&H)[21].

The Genomics England 100,000 Genomes Project[22], established in 2013, aimed to sequence 100,000 whole genomes from NHS patients to facilitate incorporating genomic medicine into routine healthcare, delivered through 14 Genomic Medicine Centres across England.

Collections were based on two themes: rare disease and cancer, with sequenced data being linked to its associated clinical data and then being made available to researchers within a dedicated trusted research environment (TRE). The US TCGA[23] is a comprehensive programme comprising molecular and clinical data from over 20,000 samples spanning 33 cancer types. The multi-omics data generated from sequencing and array-based technologies is publicly available to the research community for use in projects as a research or validation dataset. The BCN Biobank[24] is the UK's largest unique breast cancer disease-specific collection of high-quality specimens, comprising tissues, serial liquid biopsies and bespoke cell lines, and longitudinal clinical data derived from primary and secondary electronic healthcare records (EHRs). Finally, G&H[25] is a community-based general health study that recruits individuals of Pakistani and Bangladeshi origin within the East London, Bradford and Greater Manchester areas. These participants are consented for lifelong access to their primary and secondary EHRs and a saliva sample for genetic studies.

Pan-cancer and breast cancer-specific sequencing initiatives, such as TCGA, the International Cancer Genome Consortium (ICGC)[26] and METABRIC[27], represent invaluable data assets for breast cancer research. While information pertaining to ethnicity is not available for the METABRIC cohort, those of the TCGA and ICGC data are comprised of the dominant ethnicities of their sampled cohorts White, Black and East Asian.

There is a significant underrepresentation of data from collections within South Asian populations. The paucity of data on a group that comprises up to 20% of the world's population is now recognised[28], with initiatives attempting to reduce this research inequality. The collection of data from South Asian patients in this study represents one of the largest UK South Asian breast cancer cohorts currently available.

Our study harnesses multimodal data available from large cohorts to improve our understanding of ancestry-associated differences in BC and highlight opportunities to address inequalities and achieve more equitable clinical outcomes (Figure 1).



Figure 1. Graphical summary of the analytical approach.

A. Four multi-modal clinical and sequenced cohorts used in this study. **B.** Data analytics and linkage, focusing on developing a framework for harmonising and linking a defined set of EHR data and deriving a research-ready dataset alongside the sequencing data. Stratification is performed based on gAncestry (EUR, AFR and SAS). **C.** Data processing workflow to explore clinical data alongside sequence data. For a given gAncestry, we explore the relationship between breast cancer clinical variables, mutational profiles and regulators of drug response. **D.** This framework supports the use of multi-modal longitudinal EHRs and sequencing in breast cancer to inform care for under-represented AFR and SAS groups.

RESULTS

Cohort Characteristics

The study dataset comprised 7,136 breast cancer patients from four cohorts – 3,334 from Genomics England, 2,479 from Barts Health NHS Trust patients within BCN Biobank (BCN Biobank-Barts cohort), 1,076 from TCGA and 363 from G&H (Figure 2). To minimise biological variability between the cohorts, the inclusion criteria were restricted to female breast cancer patients presenting with primary disease. For TCGA and Genomics England, the analytical cohort was further restricted to those patients for whom their primary tumours were sequenced and genetic ancestry (gAncestry), determined from germline sequencing, was available alongside self-reported ethnicity (SRE). For the BCN Biobank-Barts cohort, sequencing data, and gAncestry, were only available for 231 patients that were dually consented to BCN Biobank and Genomics England. For the rest of the BCN Biobank-Barts cohort, SRE was used. The G&H cohort, wholly consists of South Asian British participants.



Figure 2. Study schema of the four cohorts – Genomics England, TCGA, BCN Biobank-Barts cohort, G&H.

For Genomics England, 2,840 patients passed initial QC (see Methods), of whom 2,781 also had gAncestry available (see Methods for the method of gAncestry determination). This analytical cohort comprised European (EUR, n=2,343 (84.3%)), African (AFR, n=138 (5.0%)), South Asian (SAS, n=123 (4.4%)), East Asian (EAS, n=37 (1.3%)), American (AMR, n=12 (0.4%)) and Admix (Admix, n=128 (4.6%)) populations (Supplementary Figures 1 and 2). The gAncestry profile of the TCGA analytics cohort (n=1,064) differs in its composition of Asian gAncestry groups to Genomics England and comprises EUR (n=821 (77.2%)), AFR (n=125 (11.7%)), SAS (n=4 (0.4%)), EAS (n=56 (5.3%)), AMR (n=5 (0.5%)) and Admix (n=125 (11.7%)) gAncestry populations (Supplementary Figure 2).

Following initial filtering for women with primary disease, the ethnic distribution of the BCN Biobank analytical cohort (n=2,126) was as follows: White (n=1,332 (62.7%)), Black/Black British (n=321 (15.1%)), Asian/Asian British (n=234 (11.0%)), Other Ethnic group (n=142 (6.7%)), Mixed (n=56 (2.6%)), and not stated/unknown (n=41 (1.9%)) (Supplementary Figure 2). As G&H is an initiative looking at more general health concerns within the South Asian British population, the participants without a history of breast cancer were excluded (53,393 out of 53,756), leaving 363 in the analysis cohort.

Patients within the AMR and EAS gAncestry groups were removed from the final analytical cohorts due to the small sizes of the cohorts, which would significantly reduce the power of any statistical inference on this cohort: both gAncestry groups map onto the Other Ethnic Groups ethnic category for Genomics England and BCN Biobank. Furthermore, the limited number of participants in the TCGA SAS population (n=4), precludes the use of this population as a validation for SAS v EUR comparisons. The clinical and molecular analyses in this study focus on the EUR, AFR and SAS gAncestry superpopulations (which significantly overlap with White, Black and South Asian SRE groups) within all cohorts.

To determine the ethnic representativeness of the cohorts relative to the geographical region of collection, SRE was compared to that of the UK Census data for Genomics England and the BCN Biobank-Barts cohort. The ethnic composition of the Genomics England cohort broadly recapitulates that of England (2021 UK Census data – Supplementary Figure 2) with 81.0% White, 4.2% Black/Black British, 9.6% Asian/Asian British, 3.0% Mixed, 2.2% Other. However, it is not comparable to that of London, which comprises a higher proportion of ethnic minority groups (53.8% White, 13.5% Black/Black British and 20.7% Asian/Asian British). The BCN Biobank-Barts cohort closely resembles the London statistics, likely representing the ethnic composition of the area around the key collection site in North East London (Supplementary Figure 2a). The gAncestry composition of the TCGA analysis cohort (Supplementary Figure 2b) presents a higher proportion of AFR gAncestry and a much lower proportion of SAS gAncestry relative to Genomics England (AFR, 11.5% in TCGA v 5.0% in Genomics England; SAS, 0.4% TCGA v 4.4% Genomics England) recapitulating the diversity of the geographically diverse TCGA data collection centres.

Concordance Between SRE and gAncestry

There is high, almost identical, concordance between SRE and gAncestry in Genomics England (92.9%) and TCGA (92.3%) (Figure 3a, Figure 3b). Concordance between the BCN Biobank SRE and gAncestry for dually-consented patients is 88.5%. This figure improves to 94.5% if the Discovery Data Service[29] is used to improve stated ethnicity. Patients assigned to the Admix cohort in Genomics England represent the greatest source of discordance between SRE and gAncestry, with 50% concordance between a mixed SRE and Admix gAncestry. The gAncestry fractions for individual patients within the Admix population in Genomics England are shown in Supplementary Figure 1.



Figure 3. Concordance between SRE/race and inferred gAncestry: **a.** in the Genomics England cohort; and **b.** in the TCGA breast cancer cohort.

Descriptive Statistics of Clinical and Molecular Features

We explored the associations between gAncestry and key clinical or molecular variables by applying linear regression models for numeric covariates, such as age at diagnosis, age at death and log tumour mutational burden, and logistic regression models for categorical covariates, such as receptor status, tumour stage and grade. The group comprising the largest number of individuals, EUR, was used as a reference against which all other gAncestry groups were compared (Figure 4a, Supplementary Table 1, Supplementary Methods).

The results for Genomics England indicate that AFR and SAS women present to the clinic with BC significantly earlier (5.28 and 6.91 years, respectively, $p<0.001$) and die at a younger age (8.94 and 13.20 years earlier, respectively, $p<0.05$) than their EUR counterparts (Figure 4a, Supplementary Table 1). Patients in the AFR cohort also present with higher grade tumours (OR 1.88, $p<0.05$), with a higher incidence of hormone receptor negative (HR-) disease relative

to EUR (ER- OR 2.06; PR- OR 2.07, $p<0.05$). Similar findings were reported in the AFR group of the TCGA, with these patients presenting at a younger age (4.06 years earlier, $p<0.0015$) and with increased HR- disease compared to the EUR group (ER- OR 2.9, PR- OR 2.37, $p<0.001$) (Supplementary Figure 3, Supplementary Table 5). There is a tendency for AFR patients to present with similar ancestry-corrected tumour mutational burden (TMB) to their EUR counterparts, with TMB showing a propensity to be lower in the SAS cohort.

A relationship was observed between gAncestry and quintiles of index of multiple deprivation (IMD) within Genomics England, with AFR and SAS patients more likely to reside in areas within the more deprived quintiles, an association that is pronounced in the former (Figure 4a, Supplementary Table 1). Tests to determine whether IMD was confounding the analyses for the other covariates showed no significant difference when adding IMD as the second variable (Supplementary Table 2), with only the age at diagnosis showing an improvement in fit (X^2 = 14.0 (4 df), $p = 0.007$). A test of covariates versus IMD alone for the largest gAncestry group (EUR) show that these patients in the most deprived quintile present 2.38-3.12 years earlier than those in the other four quintiles, where age at diagnosis was similar. No other factor was significantly associated with IMD (Supplementary Table 3).

Associations between these clinical covariates and SRE, used as a proxy for gAncestry, were investigated in the BCN Biobank dataset. In agreement with our genomic-based findings, Black and South Asian patients in the BCN Biobank presented earlier (2.54 years, p.adj < 0.01 and 2.75 years p.adj < 0.05, respectively) and died at a younger age (6.49 years, p.adj < 0.05 and 6.21 years, p.adj = 0.146, respectively) relative to their White counterparts (Supplementary Figure 3, Supplementary Table 4), although the difference between the populations is smaller. Examining the IMD distribution from dually consented EUR patients within Genomics England shows that this particular subset derives from areas of higher deprivation, which may account for the reduction in effect size. Furthermore, patients within these ethnic groups also

tended to present with aggressive – significantly higher frequencies of high-grade tumours and lymph node involvement – HR- disease.

We examined each gAncestry group within Genomics England split based on a 50-years-old cut-off, to represent the age at which the NHS breast screening is initially offered to individuals, however this resulted in small numbers of participants in these sub-groups, increasing the uncertainty in our point estimates (Supplementary Figure 4).

Patients within the <50-year-old AFR group show a propensity to present with higher grade tumours, HR- disease and a HER2+ receptor status. In addition, the TMB of this younger cohort tends to be higher than their EUR counterparts (Supplementary Figure 4). The clinical features of the <50-year-old SAS group are like those of the corresponding EUR group, bar a potential trend towards PR- disease, a trend that appears inverted in the ≥50-year-old group. Further examination of TMB trends stratified by ER status across the cohort identified higher median TMB in ER- patients (2.54 muts/Mb) compared to ER+ patients (1.33 muts/Mb; $p < 2.2e-16$). Finally, as observed in the unstratified analysis, non-EUR patients in the ≥50-year-old cohort died at a younger age (5.80 years and 9.47 years earlier for AFR and SAS, respectively, $p<0.05$) (Supplementary Figure 4).

The age at diagnosis curves for each gAncestry show differences between the three populations. The EUR distribution curve of age at diagnosis in the Genomics England analytical cohort is platykurtic relative to the non-EUR groups, with two modes of similar heights at 51 and 70 years (Figure 4b). There is a unimodal age distribution for patients of AFR and SAS gAncestries, with prominent peaks at 47 and 49 years, respectively.

The age distribution of the EUR cohort of the TCGA exhibits a mild bimodal distribution, with the highest peak presenting at 63 years and the mean age at diagnosis being similar to that of the Genomics England analytical cohort (59.42 years and 61.7 years, respectively) (Figure 4b,

Supplementary Table 5). The White cohort from BCN Biobank, whilst showing a larger IQR than non-White cohorts, appears to shift towards a younger age at presentation (58.41 years) (Figure 4b, Supplementary Table 4). As mentioned, this could be attributable to the BCN Biobank recruitment centre being located close to areas of higher deprivation in North East London. Similar trends in age distribution profiles are observed between the AFR/Black cohorts of Genomics England, TCGA and BCN Biobank, and the SAS/South Asian cohort of Genomics England and G&H (Figure 4b, Supplementary Tables 4 and 5). The South Asian cohort of the BCN Biobank exhibits a wider peak than that from both Genomics England and G&H, although the mean age of diagnosis is similar (BCN Biobank 55.2 years; Genomics England 54.8 years) (Figure 4b). This may be due to the differences between ethnic subgroups within BCN Biobank: Bangladeshi patients (n=82) had a mean age at diagnosis of 53.99 (s.d. = 11.94 years); Pakistani patients (n=65) had a mean age of 54.37 (s.d. = 12.54); but the Indian patient group (n=87), had a mean age of 57.20 (s.d. = 10.03).

We stratified each gAncestry cohort within Genomics England based on the central 60% of the age distribution, to improve equity between the cohorts in breast screening. Current guidelines apply at the 20th percentile in the EUR age distribution, so we placed the lower bound on the intervals at that percentile in the other gAncestries. We also increased the upper bound to the upper 20th percentile of the age distribution. This resulted in gAncestry-specific intervals: 50-75 years (EUR), 47-69 years (AFR) and 45-68 years (SAS) (Figure 4c). With gAncestry not readily available in the clinic, we isolated patients with concordant ethnic and gAncestry assignments and confirmed the applicability of these modified windows (Supplementary Figure 5). Applying the screening windows to BCN Biobank patients not dually-consented with Genomics England, gives better coverage for all three major ethnic groups: 67.4% (793/1176) within White patients, 64.8% (190/293) within Black patients and 70.5% (148/210) coverage within Asian patients, and applying the suggested Asian age window to the G&H

cohort would improve coverage from 26.4% (96/363) for the standard 50-70 window to 59.2% (215/363) coverage within this group.



Figure 4. a. Forest plots of the clinical and molecular features of the non-EUR cohorts relative to EUR. **b.** Age of diagnosis distributions for EUR (Genomics England/TCGA)/White (BCN Biobank), AFR (Genomics England/TCGA)/Black (BCN Biobank), SAS (Genomics England)/Asian (BCN Biobank and G&H). **c.** Visualisation of the gAncestry-derived screening windows in the Genomics England cohort.

gAncestry-Associated Somatic Variants within the Genomics England Cohort

The variant landscape of the TCGA cohorts has been described previously.[6] To determine gAncestry-associated somatic variant profiles within the Genomics England cohort, two models were applied to identify differentially mutated genes and variants relative to the EUR comparator: logistic regression, and a threshold criterion. The latter was implemented to identify variants exclusively present in one cohort, where the application of a logistic regression model fails to converge (Supplementary Methods).

Significant differences in the mutational frequencies of 481 genes in AFR group and 275 genes in the SAS group were observed (Supplementary Table 6). Of these, the logistic classifier identified 2 and 19 genes (Figure 5) and the threshold classifier 480 and 268 genes in the AFR and SAS cohorts respectively (Supplementary Table 6). Six genes (*RBM5*, *OTOF*, *FBXW7*, *NCKAP5*, *NOTCH3* and *GPR158*) were found commonly differentially mutated between the AFR populations of the Genomics England and TCGA cohorts.

We identified 71 variants with significant differences in mutational frequencies in the AFR cohort and 60 variants in the SAS cohort (Supplementary Table 7). Of these, the logistic classifier identified 7 and 4 variants (Figure 5) and the threshold classifier 71 and 59 variants in the AFR and SAS cohorts respectively (Supplementary Table 7).



Figure 5. Genes and variants identified as differentially mutated in non-EUR versus EUR gAncestry (in the Genomics England cohort) by the linear regression model.

Germline Variant Profiles of Cancer Susceptibility Genes

Genomics England was the only cohort for which sufficient germline genomic variant data was available to allow for comparisons to be made between gAncestry (or ethnic) groups (the G&H germline data has not been released yet for the whole cohort). Within this cohort, we compared the AFR and SAS gAncestry groups against the EUR baseline by conducting logistic regression analyses focussing on variants within germline genes currently tested in the clinic and those reported to exhibit ancestry-associated differences in the literature.[11,30-34]

Differences in the prevalence of germline variants of cancer susceptibility genes were observed between the gAncestries (Figure 6, Supplementary Table 8). For genes in current genetic tests (red genes in Figure 6), the AFR and SAS groups were significantly enriched for *TP53* (AFR, OR 11.6; SAS, OR 4.16), *BRCA1* (AFR, OR 4.65; SAS, OR 2.95) and *BRCA2* (AFR, OR 4.28; SAS, OR 3.83) germline mutations relative to EUR, with the AFR population also exhibiting a higher frequency of *PALB2* (OR 10.7) mutations. Significant differential mutation patterns were also observed in an additional 11 and 8 cancer predisposing genes, from those identified

from the literature-based searches (blue genes in Figure 6), in the AFR and SAS population, respectively, with a propensity for these to exhibit more mutations in genes associated with DNA damage response (Supplementary Table 8). To test whether ER status could be confounding this analysis specifically for germline *BRCA* mutations, we split the Genomics England analytic cohort by ER status and found a small difference between ER- disease (9.3% of patients, n= 27/292) and ER+ disease (8.7% of patients, 141/1621), which was not significant (Fisher's exact p-value = 0.7368).



Figure 6. Frequency of mutations observed in cancer susceptibility genes. The AFR (**a**) and SAS (**b**) cohorts within Genomics England exhibit distinct landscapes of germline variants.

Validation of differential mutations within gAncestry groups and pharmacogenomic potential

Six of our genes identified as differentially mutated between EUR and AFR (*RBM5, OTOF, FBXW7, NCKAP5, NOTCH3, GPR158*) are also significantly differentially mutated in TCGA for EUR v AFR. These genes have various oncologic functions: *RBM5* and *FBXW7* have been identified as tumour suppressor genes, and *OTOF, NCKAP5* and *GPR158* as possible oncogenes.[6,35] *FBXW7* has been found to be differentially mutated in AFR populations in multiple cancer types[6,35], suggesting that this is not a cancer-specific association. Overexpression of *OTOF* (in clear-cell renal cell carcinoma)[36], *NCKAP5* (non-small cell lung cancer)[37] and *GPR158* (in prostate cancer and gliomas)[38] have been used as prognostic biomarkers of aggressive disease in these cancers. *NOTCH3* pathway expression is associated with cell proliferation and promotes breast tumour angiogenesis and metastasis.[39] Mutations in *GPR158* and *FBXW7* have potential candidate therapeutic targets, in ovarian[40], osteosarcoma[41] and BC[42], with the latter reference reporting that mutation confers resistance to paclitaxel BC treatment.

Six other differentially mutated somatic genes found across the AFR and SAS populations – *BRIP1, CDKN2A, CHEK2, KDM6A, RET, STK11* – were identified as actionable candidates for therapeutic targeting in the OncoKB Precision Oncology Knowledge Base (accessed 24/10/2023)[43] and within clinical trials[44]. Mutations in *BRIP1*[45] confer stronger response to olaparib; *CHEK2*, only confers response to olaparib when mutated in the germline, and then only in combination with other somatic mutations[46]. Inactivating mutations in *CDKN2A* improve response to abemaciclib, palbociclib and ribociclib[47]; loss-of-function mutations in *KDM6A* improve response to tazemetostat[48]; fusion mutations in *RET* to selpercatinib[49] and mutations in *STK11* to the combination therapy of bemcentinib and pembrolizumab[50], but many of these results are not in breast cancer.

The clinically-actionable targets from the differentially mutated genes (within both somatic and germline lists) are summarised in Figure 7.



Figure 7. Clinically-actionable targets found differentially mutated within Genomics England breast cancer cohorts.

Survival analyses of the differentially mutated somatic and germline variants on our cohorts split by gAncestry did not show differences in survival for those mutations (data not shown)[51]. However, the analysis is limited by the short length of follow-up data on several participants, leading to a dominant right-censored data effect that adds bias to the survival estimates.

Mutational Signatures and Homologous Recombination Deficiency

To determine the contribution of environmental exposures to differences in mutation frequencies between the gAncestry groups within Genomics England, we implemented the signature.tools.lib R library[52] to perform mutational signature analyses confined to breast-specific parameters.

Our dataset comprised 32,558,096 substitutions, 339,207 double substitutions, 15,384,289 indels, and 489,339 rearrangements (Table 1). There are significantly more substitutions, double substitutions, and rearrangements per patient in the AFR group, and fewer indels, whereas the SAS group tended to mirror this trend with fewer substitutions, double substitutions and rearrangements but more indels.

	EUR (n=2343)	AFR (n=138)	SAS (n=123)
Substitutions	29,262,814 (12,489.5/patient)	1,927,230 (13,965.4/patient) *	1,398,052 (11,366.3/patient)
Double substitutions	304,340 (129.9/patient)	19,134 (138.7/patient) **	15,733 (127.9/patient)
Indels	13,733,867 (5,861.5/patient)	660,062 (4,783.1/patient) *	990,360 (8,051.7/patient)
Rearrangements	436,604 (186.3/patient)	31,063 (225.1/patient) ***	21,672 (176.2/Patient)

Table 1. Types of somatic variation present in each gAncestry, with comparisons made against EUR (* <0.05, ** <0.01, *** <0.001).

Three common signatures were identified as occurring in significantly differing proportions in the AFR or SAS group relative to EUR (Figure 8a). SBS1 (associated with increasing age) and SBS3 (associated with homologous recombination deficiency) were reported in high proportions across all gAncestry groups (SBS1 EUR 95.2%, AFR 99.3%, SAS 94.3%; SBS3 EUR 90.3%, AFR 97.8%, SAS 87.8%, Supplementary Table 9a), with a significant increase in frequency observed in the AFR population. SBS2 (APOBEC) was significantly lower in the SAS group relative to EUR. The rare SBS57 (identified as a possible sequencing artifact) was observed at a significantly higher frequency in the SAS group.

The double base substitution signature DBS12 (correlated with SBS105) was more prevalent in the AFR group (Supplementary Table 9b), with the other double base signatures showing similar proportions across all three groups. Rearrangement signatures RefSig R4 (dominated by clustered translocation patterns, associated with *CDK4* driver mutations) and RefSig R5 (characterised by unclustered deletions <100kb) were more prevalent in AFR group, with a trend towards lower prevalence of both RefSig R4 and RefSig R5 in the SAS population (Supplementary Table 9c).

The supervised lasso logistic regression model HRDetect was used to determine homologous recombination (HR) deficient (or *BRCA1/2* deficient) tumours (Figure 8b). There is a trend for more HR deficiency within the AFR population (17/138 – 12.3%) and lower HR deficiency within the SAS population (10/123 – 8.1%) against the EUR population baseline (225/2343 – 9.6%) (Supplementary Table 10a). While the AFR population exhibits higher proportions of SBS3 (Figure 8a, Figure 8b), this trend is reversed in the stratified HR-deficient groups, with SBS3 presentation lower in the AFR HR-deficient group relative to that of the EUR population. Similarly, the RefSig R5 rearrangement contribution is also significantly higher in the AFR HR-deficient group. This suggests that the mechanism of HR deficiency could be different for different gAncestry groups. In HR-deficient SAS tumours, the contribution from deletions with microhomology is significantly higher compared to the HR-deficient EUR tumour baseline. Trends towards lower contributions from deletions with microhomology and loss-of-heterozygosity are seen in HR-deficient AFR tumours, although this is not significant. HR-deficient SAS tumours tended to have lower RefSig R5 contributions, but a similar loss-of-heterozygosity score to those of HR-deficient EUR tumours (Supplementary Table 10b).

Survival analyses[51] splitting the cohort into HR-deficient and HR-proficient groups showed that, although the mechanisms of HR deficiency are different between the cohorts, overall survival for HR-deficient tumours was significantly lower than HR-proficient tumours

(p<0.001, HR 2.4, Supplementary figure 6). However, when further stratifying the cohort by gAncestry, only the EUR remained significant (p<0.001, HR 2.5). This is due to the small numbers of HR-deficient patients with survival data within the AFR (n=16, p=0.741, HR 1.3) and SAS cohorts (n=10, p=0.168, HR=2.8), leading to large confidence intervals. Again, though, there is significant right-censoring of data due to the shortness of follow-up data.



Figure 8. Mutational signatures and Homologous Recombination Deficiency. **a.** Mutational signatures within each cohort with significance computed using EUR as reference. **b.** Relative contributions of each component of the HRDetect scores used to determine BRCA1/BRCA2 deficient tumours in the gAncestry groups. Stars above each split violin indicate significant differences compared to the EUR baseline (* <0.05, *** <0.001).

METHODS

Data Collection and Collation

Genomics England clinical data

For the clinical data for our Genomics England cohort, the following tables within the Genomics England TRE (v17; March 2023) were queried using LabKey *via* the R/LabKey API. The relevant participant IDs were identified from the *cancer_participant_disease* table, with other primary and secondary tables queried using these unique Participant IDs as primary keys (Extended Methods). This gave an initial BC Genomics England cohort of 3,336 participants.

One participant was in the database twice under two participant IDs, flagged under a *duplicate_participant_id* entry; one further participant withdrew consent before the v17 data release, leaving 3,334 BC participants in the initial investigative cohort.

For each selected data item, a single entry was consolidated for each participant, using the primary data source. In the absence of primary data, data from the secondary source was used, with information extracted from the record closest to diagnosis date, unless explicitly stated otherwise (Extended Methods). Upon collation, the clinical information of the patient with duplicated IDs was assessed for discrepancies and the duplicated information was removed, with the earliest date selected to represent date of diagnosis.

The final analytical cohort was determined following clinical and genomic criteria for exclusion as described in the previous section (Figure 2), with three further samples removed following QC checks based on TMB calculations.

BCN Biobank clinical data

The BCN Biobank extract (accessed 27/04/2023) comprised 2,479 patients from Barts Health (BH) NHS Trust. BH is the largest NHS trust in London with five hospitals (St Bartholomew's Hospital, The Royal London Hospital, Mile End Hospital, Newham Hospital and Whipps Cross University Hospital) serving 2.5 million people across the diverse population of North East London. BCN Biobank-Barts data are linked to EHRs from BH via the NHS or hospital number. 2,126 were female and had complete clinical data associated with incidence of unilateral primary BC. Of these, the genomic data from 195 samples were available from the Genomics England TRE as these patients were consented by both BCN Biobank and Genomics England. Basic demographic statistics (age, ethnic group) was updated using linkage between this dataset and the primary care data set from Discovery East London programme[29] (extract date 16/11/2023). Concordance between reported ethnicity (within BCN Biobank) and gAncestry for the dually-consented patients is 88.5%, for the primary care data alone the concordance is 86.8%. Using primary care ethnicity data when not specified in BCN Biobank improves concordance between the reported ethnicity and gAncestry to 94.5%.

With the South Asian ethnic group being a focus of the study, participants from "Any Other Asian Background" were moved to the "Other" ethnic category to prevent dilution with possible Middle-Eastern, Chinese or other South-East Asian ethnic groups. The calculated BCN Biobank age at diagnosis was used within the Genomics England cohort for those patients who were dually consented.

TCGA clinical data

TCGA clinical data for the TCGA-BRCA study (n=1,098) was downloaded from the Genomic Data Commons Data Portal[53], and filtered for all those cases with neoplastic breast disease (n=1,076). This was further filtered to remove male patients, leaving 1,064 cases.

G&H clinical data

We used the G&H clinical dataset (December 2023 release), selecting 53,393 volunteers with basic demographic information available (55.4% female; 44.6% male) through primary care records from Discovery East London programme or secondary care records from Barts Health NHS Trust and NHS Digital. We filtered the available data to define individuals with breast cancer (n=363), if the EHR contains a clinical code (ICD-10 or SNOMED CT diagnosis) indicative of the present or past malignancy of breast.

Genomics England genomic data

All genomic data is accessible from the Genomics England TRE. Samples of germline genetic material and tumour tissue were sequenced, mapped to the hg38 genome assembly, and variants called: germline variants using the Isaac single sample short variant caller and somatic short variants using Strelka2[54] on the somatic and matched germline. Larger copy number changes and structural variants were called using the Manta[55] (structural variant calling) and Canvas[56] (copy number changes) pipelines. Genomics England reports of small variants (SNVs and indels) were obtained from the *cancer_tier_and_domain_variants* table, with locations for the raw data held in the *cancer_analysis* table.

Ancestry inference was conducted by Genomics England as described previously.[57] In brief, a random forest classifier was applied on the first 8 principal components derived from 188,382 good quality SNP locations within the 1000G phase3 data. The classifier generated 400 trees, with the proportion of trees classifying a germline vcf into a gAncestry superpopulation (AFR, EUR, EAS, SAS, AMR). Assignment of a sample into a gAncestry group was performed using a ≥ 0.8 proportion threshold, with individuals in the Admix group defined as those without a gAncestry proportion exceeding the defined threshold. The superpopulation proportions for each vcf are available from the *aggregate_gvcf_sample_stats* table in Genomics England.

TCGA genomic data

Simple somatic variation data for all TCGA-BRCA patients was downloaded from the GDC data commons, and then filtered using the TCGA participant ID for our TCGA cohort. The gAncestry calls were accessed from a previous study[6] that defined the consensus ancestry call from five calling methods.

Data Analysis

Demographic and clinical features

Demographic data from the non-White/non-EUR cohorts were compared against the White/EUR reference using methods described previously.[6] Where age at diagnosis and age at death were available, a linear model was applied; similarly, a linear model was applied to the log-transformed tumour-mutation burden. For other variables, a logistic regression was performed, with upper levels of the factor compared against the reference level. For Genomics England, upper levels with small numbers (particularly in the AFR and SAS gAncestry groups) were grouped together. For receptor statuses, positive receptor status was taken as the reference level.

In Genomics England, because of the potential confounding effect of IMD on demographic data, we performed two tests. Firstly, a nested likelihood ratio test of the demographic factors was conducted, comparing a reduced model (gAncestry as sole predictor) with a full model (gAncestry and IMD as predictor variables), using the lmtest R package (v 0.9-40). Secondly, the association between IMD and other demographic factors were tested within the Genomics England EUR gAncestry group, using the arsenal R package (v 3.6.3).

Tumour mutational burden

Tumour mutational burden for the Genomics England cohort was calculated following the method previously described[58], correcting for gAncestry. The chosen gAncestry reference population within gnomAD[59] was AFR for AFR, SAS for SAS and NFE (non-Finnish

European) for EUR. Non-synonymous somatic variants within exonic regions were filtered based on the relevant gnomAD population frequency, the COSMIC database[60] and the TOPMED (v3) database[61].

A mutation was retained if it satisfied one of the following criteria: (i) gnomAD population frequency was ≤ 0.1%, VAF was ≥ 3% or < 3%, and annotated by at least two COSMIC identifiers or (ii) if the relevant gnomAD population frequency was > 0.1% but ≤ 10 and annotated by at least two COSMIC identifiers. The variant was discarded if it appeared in the TOPMED database at a frequency > 0.1%. The count of retained mutations per sample was divided by the size of the exome (≈ 35.4 Mb) and multiplied by 10^6 to calculate the TMB per Mb of exome.

Differential somatic variation determination (Genomics England cohort)

Once the filtered variant list from the TMB calculation was determined, both mutated genes and the individual variants were collated separately. For each gene or variant in the lists, a logistic regression was performed of the following form (comparing AFR v EUR and SAS v EUR separately):

$$Gene \text{ or } variant \sim gAncestry + Age\ at\ diagnosis,$$

where gAncestry was 1 for AFR or SAS and 0 for EUR. If the adjusted p-value for the gAncestry odds ratio was less than 0.1, the gene or variant was considered differentially present. However, in the cases where variants were not present in one of the two comparative cohorts, the algorithm did not converge, and so a second method was employed.

In this second method, mutated genes or variants were marked as present or absent in a cohort if present at above or below 2% in the gAncestry group (a threshold of 47/2343 in EUR, 3/138 in AFR and 3/123 in SAS). The thresholded lists of genes and variants present in each cohort were intersected to give seven sets of intersections (EUR only, AFR only, SAS only,

EUR+AFR, EUR+SAS, AFR+SAS, EUR+AFR+SAS). For our purposes, we examined those genes or variants present at above 2% in AFR only and above 2% in SAS only, with the implication that they are present at <2% in the other two cohorts.

For the logistic regression model, given the sample sizes for each gAncestry within Genomics England, we have 90% power to detect an OR 5.86 (SAS)/5.12 (AFR) down to 1.97 (SAS)/1.89 (AFR) as mutation frequency increases from 5% to 25% in the minority gAncestry.

Germline variations (Genomics England cohort)

The Genomics England report of germline variants was filtered on a list taken from current clinical practice, and susceptibility genes reported in the literature[11,30-34].

As per the demographic calculation, a logistic model was fitted for the forest plots:

$$Variant\ present \sim gAncestry$$

The non-synonymous variants in each germline gene tested were plotted in co-lollipop plots using the maftools R package[62], comparing a non-EUR cohort with the EUR reference.

Signature and HRDetect calculation (Genomics England cohort)

The HRDetect[52] predictor was used to detect BRCA1/BRCA2-deficient tumours within our Genomics England analytical cohort. Here, the somatic short-variant vcfs available within the Genomics England TRE were split into SNVs and indels without filtering and the somatic copy number vcfs were split into SVs and CNVs. The R library was used to process the SNVs into SNV and DNV catalogues, and the SVs into SV catalogues. Finally, the HRDetect function was applied on the four categories of somatic variants (SNPs, indels, SVs and CNVs) to compute the homologous recombination deficiency score using their pretrained classifier.

Survival analyses (Genomics England cohort)

Survival analysis was performed as in the recent pan-cancer Genomics England paper[51], using the code and methods provided, on our cohort, both as a whole, and split between the three gAncestry groups EUR, AFR and SAS.

DISCUSSION

We present a comprehensive analysis of clinical and molecular features associated with African and South Asian genetic ancestry from a cohort of 7,136 breast tumours. Our findings highlight the importance of addressing the racial disparity in research to optimise precision oncology, ameliorating outcome, and guiding the patient clinical journey.

Self-reported race is a complex social construct that fails to capture the complexities of genetic variations and how these can influence disease pathology and response to treatment incongruent with genetic ancestry.[3,14,63] In agreement with previous research, we report a high concordance between self-reported race and genetic ancestry.[6,64] Use of the latter for the stratification of populations not only promotes equity, clarity and reproducibility in research methods but also allows for greater examination into the genetic diversity of a population and how this diversity influences disease pathology and response to treatment.

When considering clinical associations whose effect sizes are biologically meaningful, we report non-EUR/non-White populations to present at younger ages, experience more clinically aggressive HR- disease and suffer from a higher mortality rate relative to the EUR/White population.[5,7,65,66] For the Genomics England cohort, where IMD is available, the distribution of IMD within non-EUR participants within our dataset is skewed to higher deprivation quintiles compared to EUR participants. Testing IMD as a confounding factor did not reduce significance, aside from patients presenting on average 3 years younger when comparing within the EUR cohort. Despite this, it is important that patient cohorts are socio-economically matched as closely as possible to reduce this potentially confounding effect. Even after this matching, there may still be disparities in outcome, as differences in allostatic load between cohorts will also influence disease presentation, progression, and treatment. Systemic barriers to accessing health care may also contribute to differing outcomes.[67,68]

It is debatable as to whether current screening guidelines, in which a single age-based window is applied, benefit all women equally.[5,69-73] The AgeX and UK Age trials examined the feasibility of lowering the age at which patients are first invited for routine BC screening. While our study did not examine mortality statistics, results from the AgeX trial, which aimed to amend the screening window to 47-73 years, reported a 24% reduction in mortality.[70,71] Similarly, the UK Age trial, which investigated the benefits of initiating mammography screening at the age of 40 or 41, demonstrated a 25% reduction in BC mortality after 10 years.[28] However, these findings did not examine ethnicity as an independent factor, thus the long-term benefits of these strategies on reducing BC mortality in women from ethnic minority groups remain largely unknown.

Our findings support the premise that current screening guidelines detect imbalanced proportions of BC between the gAncestry groups and that ethnicity–adapted screening windows would allow for greater equity in the screening process. This includes adjusting the screening range for non-EUR cohorts to start at a younger age: in the Genomics England cohort, the revised windows would be EUR 50-75 (to detect 59.47% of BCs), AFR 47-69 years (to detect 61.31% of BCs), SAS 45-68 years (to detect 59.35% of BCs). Applying these screening windows to BCN Biobank patients not dually-consented with Genomics England gives increased coverage – White 67.4% (793/1176), Black 64.8% (190/293); Asian 70.5% (148/210), as does applying these new windows to the G&H data improving coverage from 26.4% (96/363) to 59.2% (215/363) coverage within this group. The extra coverage in BCN Biobank patients could be explained by the potential effect of the socioeconomic factors (as represented by estimated IMD) for these groups compared to Genomics England.

The appropriate designation of a bespoke screening model, which would provide an indicative screening window and guide the modality to be used during the screen, requires the interplay of multiple complex factors, such as demographics, family history of inheritable cancers,

mammographic density, previous benign breast conditions and the results of genetic testing for gAncestry-based susceptibility genes. Input from patient advocates and representation from social groups with low current uptake are also necessary to increase the penetrance of earlier intervention, working to reduce reluctance in seeking medical assistance or taking part in screening.

No significant differences in TMB between non-EUR and EUR patients were reported within Genomics England, although a trend towards higher TMB was observed in the <50 AFR cohort. These observations could be due to the association of increased TMB in ER- breast cancer, of which a higher proportion are present in the <50 AFR cohort compared to the <50 EUR cohort.

Literature associating TMB with gAncestry or ethnicity reports that AFR patients tend to have a higher TMB relative to EUR.[74,75] The corresponding trend in Asian patients is equivocal, with reports of TMB being both higher and lower in this group relative to EUR.[74-76] This is likely due to the combination of the presence of EAS and SAS gAncestry within Asian study groups, with no distinction made between the two.

Although, overall, higher TMB is associated with poorer survival in many cancers including BC,[77] very high TMB (≥ 50 mut/Mb) has been reported to have a protective effect in immunotherapy-naïve patients,[78] where it is attributed to increased cell lethality from extreme genetic instability. TMB, both in isolation and in combination with expression markers, has also been reported as a potential predictive biomarker of response to immune checkpoint inhibitors (ICIs) and has been associated with better treatment response and improved outcomes.[79,80] Estimating TMB from tumour-only sequencing (whether WGS, WES or targeted gene panels) is commonly used to determine suitability for ICI treatment, but this may exacerbate disparities between ethnic groups. This is because reference data is predominantly based on EUR gAncestry groups, meaning non-EUR gAncestries are likely under-represented.

This reference data is used to identify and remove potential germline variants and true non-EUR gAncestry germline variants can persist after filtering, inflating the estimation of TMB in ethnic minority groups and the use of ICI treatments, which confer no significant benefit. Correcting the estimated TMB for gAncestry in this case is imperative.[58] The present study used somatic variants called from paired sequencing, allowing the patients' own germlines to be used for accurate calculation of the TMB.

Six of our genes identified as differentially mutated between EUR and AFR (*RBM5, OTOF, FBXW7, NCKAP5, NOTCH3, GPR158*), which were also significantly differentially mutated in TCGA for the same comparison, have various oncologic functions. *RBM5* and *FBXW7* as tumour suppressors and *OTOF*, *NCKAP5* and *GPR158* as potential oncogenes[6,35]. Mutations in *FBXW7* are found across multiple cancer types in AFR populations[6], suggesting this is not limited to breast cancer. Overexpression of *OTOF*[36], *NCKAP5*[37] or *GPR158*[38] have been as prognostic biomarkers of aggressive disease, again not in breast cancer. The *NOTCH3* pathway expression is associated with cell proliferation and thus angiogenesis and metastasis[39]. Mutations in *GPR158* and *FBXW7* have potential candidate therapeutic targets, in ovarian[40], osteosarcoma[41] and BC[42], with the latter reporting the mutation confers resistance to paclitaxel BC treatment.

Six other somatic genes - *BRIP1, CDKN2A, CHEK2, KDM6A, RET, STK11* – were identified as actionable candidates for therapeutic targeting in in the OncoKB Precision Oncology Knowledge Base (accessed 24/10/2023)[43] and within clinical trials[44]. *BRIP1*[45] and *CHEK2*[46] mutations confer response to olaparib (*CHEK2* specifically in germline and in combination with other mutations). *CDKN2A* inactivation enhances CDK4/6 inhibitor activity[47]; *KDM6A* inactivation improves response to tazemetostatWang, et al. [48]; *RET* fusions enhance response to selpercatinib[49] and *STK11* mutations improve response to bemcentinib and pembrolizumab combination therapy. These findings, except for *BRIP1*'s impact on olaparib response, have

not been studied in breast cancer, suggesting potential drug repurposing for treating breast tumours with these mutations in non-European ancestries.

This links to the broader issue of under-representation of ethnic minority groups in research and the historical merging of East Asian and South Asian populations biasing the translational implications and resources developed as a result. As an example of this, of the significantly mutated genes identified in the AFR and SAS groups, 6/754 (0.80%) were identified in OncoKB as potential therapeutic targets compared to 12/357 (3.4%) shared with, or unique to, EUR gAncestry. These findings support reports that pharmacogenomic resources were developed based on research founded on predominantly White populations.

SBS signature 8, associated with HR deficiency, and SBS signatures 2 and 13, related to *APOBEC3A* and *APOBEC3B* function, are enriched in our Genomics England AFR (SBS2 and 13) and SAS (SBS8) populations, and have also been reported in non-EUR BC.[81] There is a trend towards more HR deficiency in the AFR population and less HR deficiency in the SAS population compared to the EUR population baseline. This concurs with the finding of more *BRCA1* and *BRCA2* mutations within the AFR population overall, which suggests more somatic testing for HR deficiency and the therapeutic use of PARP inhibitors may be appropriate in this group. Germline mutations in DNA damage repair genes (such as *BRCA1, BRCA2, CHEK2* and *ATM*) are associated with lower efficiency of CDK4/6 inhibitors and endocrine therapy in advanced BC:[82,83] with patients in the non-EUR populations presenting at a later stage, this is particularly important for management of these patients. *BRCA1*- or *BRCA2*- mutated tumours also respond better to platinum therapies.[84] However, more general HR deficiency (or *BRCA*-ness) is known to confer resistance to taxane-based chemotherapies.[85]

Our findings show that the landscape of BC-associated susceptibility genes differs between the gAncestry groups. With current clinical genetic panels developed from research that would have been ethnically biased towards a White population, the panel may not accurately represent

the mutations, frequency of mutations or risk of cancer in ethnic minority populations. In agreement with previous studies, our findings show that the landscape of BC-associated susceptibility genes differs between the gAncestry groups, suggesting that germline screening protocols modified based on ethnicity could be more informative.[11,86,87]

The penetrance of *BRCA1* and *BRCA2* is known to be modified by SNPs that influence risk in general population, but the landscape of germline diversity within African populations has yet to be explored, and so there are potentially other ancestry-related germline risk modifiers that are yet to be found.[88] A similar issue arises for germline diversity within Asian populations, with SAS and EAS gAncestries each having their own distinct BRCA1/2 mutation patterns, which are similarly relatively little examined.[86,89]

We report an imbalance in our research data from Genomics England, TCGA and BCN Biobank. These three data sources are not representative of the countries they derive from, due to the limited number of collection sites in each. The largest estimate of the South Asian American population in the US is 2% of the total US population (US Census Bureau estimate, 2021), which is exemplified by the low percentage of SAS patient data available not only from TCGA but also from the ICGC Pan-Cancer Analysis of Whole Genomes project (PCAWG).[6] This reduces its utility as validation of our results for the SAS gAncestry group if the population is sampled randomly. Thus, while the TCGA dataset can only be used to validate the molecular and clinical data differences between EUR and AFR ancestries, the BCN Biobank clinical data can be used to validate clinical features across all three of our gAncestry cohorts, notwithstanding that the lead collection site of BCN Biobank is in North East London, where the IMD distribution is skewed to more deprived quintiles.

Our cohort has the largest proportion of SAS ancestry patients among studies of similar size, reflecting the population structure of England (Supplementary Figure 2a). In fact, METABRIC[27], examining 2000 tumours, focused more on molecular subtypes and did not

report ethnicity or gAncestry differences, leaving our study as the largest study which specifically examines these. The under-representation of the SAS ancestry group in international cancer-associated studies does, however, mean that the variants we report are difficult to validate in publicly available datasets. The scarcity of the stratification of Asian ethnicities in cancer research means that any study of genomic variation using these merged population data would likely be underpowered to identify alterations unique to the South Asian population. In fact, data from large-scale US-led initiatives are likely biased towards East Asian ethnicities (and ancestries) due to them recapitulating their sampling populations.

Our genomic findings are limited by the relatively small sizes of the AFR and SAS groups (120-140 patients) within our Genomics England analytic cohort of 2,781 patients. However, this is still larger than most studies which aim to determine gAncestry-related genomic differences within the breast cancer landscape. Nevertheless, this could be improved through the inclusion of more somatic tissue sequencing from our other British-based cohorts, but the overall ratio (of EUR to AFR or SAS patients) would continue to exhibit bias towards the EUR gAncestry, unless the non-EUR groups within the UK (or worldwide) were specifically targeted for collection. However, our study was still powerful enough to find significant differences between EUR and the other two groups. Any further study would need to specifically target the non-EUR groups either within the UK or worldwide to move towards equipoise and extract the more subtle variations that may not currently be apparent.

Tackling disparities in research has become a public health priority. One of the Cancer Grand Challenges[90] is focused on cancer inequities; Genomics England has recently implemented the Diverse Data initiative to bridge the ethnic data gap in genomics-driven personalised medicine; and the BCN Biobank is focusing on increasing recruitment from ethnic minority populations. Furthermore, the Breast Cancer Now's Inequalities Funding Scheme was implemented to encourage applications for research into increasing health equity within BC. These shifts in

future data and sample collections will help ensure that findings from research will be more powerful due to better equipoise in ethnic groups ensuring equitability in translational implications.

There are evident health disparities in BC diagnosis, therapeutic management, and outcome globally. While determining genetic diversity is important for the advancement of precision oncology, disparities in healthcare cannot be attributed to a single factor but rather stem from a complex web of interlinking clinical, social and genetic factors. To ensure that precision oncology benefits all patients equally, regardless of their ethnic background, it is imperative to foster trans-disciplinary co-operation and conduct multi-modal studies, that incorporate data from primary and secondary healthcare in addition to genomics.

Data Availability

Genomic and phenotypic data for the 100KGP study participants are available through the Genomics England Research Environment *via* application at https://www.genomicsengland.co.uk/research/academic/join-gecip. The clinical data and donor ancestry calls for the TCGA cohort used in this study are available from the supplemental information (Table S1) of Carrot-Zhang et al.[6] Additional clinical and genomic data for the TCGA BRCA cohort were accessed from the Genomics Data Commons Data Portal.[53]

Clinical data and specimens of dually consented patients are available from the BCN Biobank on application to the Tissue Bank, and clinical and molecular data from G&H available to researchers registered via the G&H portal.

Code Availability

Although clinical and molecular data within the Genomics England TRE have been anonymised, the data are sufficiently detailed that the data could be deanonymised through data linkage, and thus cannot be extracted directly from the TRE. All analyses and codes are

therefore available from the GitHub instance within the TRE for approved Genomics England Research Network participants.

Acknowledgements

This work was supported by Barts Charity (grant code MGU0504) and Barts NIHR BRC (grant code BTXH1A1R). BCN Biobank is funded by the Breast Cancer Now charity (grant code TB2022BAR). This work forms part of the research portfolio of the National Institute for Health and Care Research Barts Biomedical Research Centre (NIHR203330); a delivery partnership of Barts Health NHS Trust, Queen Mary University of London, St George's University Hospitals NHS Foundation Trust and St George's University of London.

This research was made possible through access to data in the National Genomic Research Library, which is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The National Genomic Research Library holds data provided by patients and collected by the NHS as part of their care and data collected as part of their participation in research. The National Genomic Research Library is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure.

The results published here are in part based upon data generated by the TCGA Research Network[19].

The authors wish to acknowledge the roles of the Breast Cancer Now Biobank in collecting and making available the samples and/or data, and the patients who have generously donated their tissues and shared their data to be used in the generation of this publication. We are especially grateful to members of the BCN Biobank-BCI (Catherine McMaster-Christie, Rachel Nelan, Jennifer McGuinness, Jenny Gomm and Iain Goulding) for their help in setting up the framework for data collection.

We thank Barts Health NHS Trust for their help with the collection of secondary and tertiary care data for BCN Biobank. We thank members of the Discovery East London Programme Board, Discovery Data Service/Endeavour Health Charitable Trust and Voror Health Technologies Ltd for their support in facilitating collection of BCN Biobank primary care patient records.

Genes & Health has recently been core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017, MR/X009777/1, MR/X009920/1), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), with research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames).

Most of all, we thank all of the individuals participating in the Genomics England 100,000 Genomes Project, The Cancer Genome Atlas, Genes & Health and the Breast Cancer Now Biobank.

REFERENCES

1 Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **71**, 209-249 (2021). https://doi.org/10.3322/caac.21660

2 Sadigh, G. *et al.* Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncol* **8**, 579-586 (2022). https://doi.org/10.1001/jamaoncol.2021.7656

3 Aldrighetti, C. M., Niemierko, A., Van Allen, E., Willers, H. & Kamran, S. C. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. *JAMA Netw Open* **4**, e2133205 (2021). https://doi.org/10.1001/jamanetworkopen.2021.33205

4 Guerra, C. E. & Viswanath, C. Advancing Equity in Cancer Clinical Trials: Lessons From the Evidence. *JCO Oncol Pract* **18**, 633-634 (2022). https://doi.org/10.1200/OP.22.00390

5 Bowen, R. L., Duffy, S. W., Ryan, D. A., Hart, I. R. & Jones, J. L. Early onset of breast cancer in a group of British black women. *Br J Cancer* **98**, 277-281 (2008). https://doi.org/10.1038/sj.bjc.6604174

6 Carrot-Zhang, J. *et al.* Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. *Cancer Cell* **37**, 639-654 e636 (2020). https://doi.org/10.1016/j.ccell.2020.04.012

7 Copson, E. *et al.* Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study. *Br J Cancer* **110**, 230-241 (2014). https://doi.org/10.1038/bjc.2013.650

8 Gathani, T., Reeves, G., Broggio, J. & Barnes, I. Ethnicity and the tumour characteristics of invasive breast cancer in over 116,500 women in England. *Br J Cancer* **125**, 611-617 (2021). https://doi.org/10.1038/s41416-021-01409-7

9 Goel, N. *et al.* Racial Differences in Genomic Profiles of Breast Cancer. *JAMA Netw Open* **5**, e220573 (2022). https://doi.org/10.1001/jamanetworkopen.2022.0573

10 Vazquez, E. D. *et al.* Chemokine receptors differentially expressed by race category and molecular subtype in the breast cancer TCGA cohort. *Sci Rep* **12**, 10825 (2022). https://doi.org/10.1038/s41598-022-14734-5

11 Yadav, S. *et al.* Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer. *J Natl Cancer Inst* **113**, 1429-1433 (2021). https://doi.org/10.1093/jnci/djaa167

12 Evans, D. G. *et al.* The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin? *Int J Cancer* **150**, 73-79 (2022). https://doi.org/10.1002/ijc.33782

13 Ho, W. K. *et al.* Polygenic risk scores for prediction of breast cancer risk in Asian populations. *Genet Med* **24**, 586-600 (2022). https://doi.org/10.1016/j.gim.2021.11.008

14 Khor, S. *et al.* Racial and Ethnic Bias in Risk Prediction Models for Colorectal Cancer Recurrence When Race and Ethnicity Are Omitted as Predictors. *JAMA Netw Open* **6**, e2318495 (2023). https://doi.org/10.1001/jamanetworkopen.2023.18495

15 Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet* **51**, 584-591 (2019). https://doi.org/10.1038/s41588-019-0379-x

16 Park, J. I., Bozkurt, S., Park, J. W. & Lee, S. Evaluation of race/ethnicity-specific survival machine learning models for Hispanic and Black patients with breast cancer. *BMJ Health Care Inform* **30** (2023). https://doi.org/10.1136/bmjhci-2022-100666

17 Kantor, O. *et al.* Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc

Analysis of the TAILORx Randomized Clinical Trial. *JAMA Surg* **158**, 583-591 (2023). https://doi.org/10.1001/jamasurg.2023.0297
18 Genomics England Limited. https://www.genomicsengland.co.uk/initiatives/100000-genomes-project (2024).
19 National Cancer Institute Center for Cancer Genomics. *The Cancer Genome Atlas Program (TCGA)*, https://www.cancer.gov/ccg/research/genome-sequencing/tcga (2024).
20 Breast Cancer Now. *Breast Cancer Now Tissue Bank*, https://breastcancernow.org/breast-cancer-research/breast-cancer-now-tissue-bank (2024).
21 East London Genes & Health. *Genes & Health*, https://www.genesandhealth.org/ (2024).
22 The National Genomic Research Library v5.1 Genomics England. https://doi.org/10.6084/m9.figshare.4530893.v7 (n.d.).
23 The Cancer Genome Atlas Research Network *et al.* The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet* **45**, 1113-1120 (2013). https://doi.org/10.1038/ng.2764
24 Abdollahyan, M. *et al.* Dynamic Biobanking for Advancing Breast Cancer Research. *J Pers Med* **13** (2023). https://doi.org/10.3390/jpm13020360
25 Finer, S. *et al.* Cohort Profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. *Int J Epidemiol* **49**, 20-21i (2020). https://doi.org/10.1093/ije/dyz174
26 Zhang, J. *et al.* The International Cancer Genome Consortium Data Portal. *Nat Biotechnol* **37**, 367-369 (2019). https://doi.org/10.1038/s41587-019-0055-9
27 Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**, 346-352 (2012). https://doi.org/10.1038/nature10983
28 Genomics England Limited. *Diverse Data* https://www.genomicsengland.co.uk/initiatives/diverse-data (2024).
29 Discovery Health and Care Data Service. *Discovery Data Service*, https://www.discoverydataservice.org/Content/Home.htm (2023).
30 Hu, C. *et al.* A Population-Based Study of Genes Previously Implicated in Breast Cancer. *N Engl J Med* **384**, 440-451 (2021). https://doi.org/10.1056/NEJMoa2005936
31 Oak, N. *et al.* Ancestry-specific predisposing germline variants in cancer. *Genome Med* **12**, 51 (2020). https://doi.org/10.1186/s13073-020-00744-3
32 Su, Y. *et al.* Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions. *Front Genet* **12**, 674094 (2021). https://doi.org/10.3389/fgene.2021.674094
33 Tung, N. *et al.* Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. *J Clin Oncol* **34**, 1460-1468 (2016). https://doi.org/10.1200/JCO.2015.65.0747
34 Genomics England Limited. *Cancer Analysis Technical Information Document v2.0*, https://re-docs.genomicsengland.co.uk/cancer_tech_1_11.pdf (2019).
35 Sutherland, L. C., Wang, K. & Robinson, A. G. RBM5 as a putative tumor suppressor gene for lung cancer. *J Thorac Oncol* **5**, 294-298 (2010). https://doi.org/10.1097/JTO.0b013e3181c6e330
36 Cox, A. *et al.* Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. *Int J Urol* **28**, 424-431 (2021). https://doi.org/10.1111/iju.14486

37 Chen, K. *et al.* Immune infiltration patterns and identification of new diagnostic biomarkers GDF10, NCKAP5, and RTKN2 in non-small cell lung cancer. *Transl Oncol* **29**, 101618 (2023). https://doi.org/10.1016/j.tranon.2023.101618
38 Patel, N., Itakura, T., Gonzalez, J. M., Jr., Schwartz, S. G. & Fini, M. E. GPR158, an orphan member of G protein-coupled receptor Family C: glucocorticoid-stimulated expression and novel nuclear role. *PLoS One* **8**, e57843 (2013). https://doi.org/10.1371/journal.pone.0057843
39 Leontovich, A. A. *et al.* NOTCH3 expression is linked to breast cancer seeding and distant metastasis. *Breast Cancer Res* **20**, 105 (2018). https://doi.org/10.1186/s13058-018-1020-0
40 Youssef, A., Haskali, M. B. & Gorringe, K. L. The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic. *Cancers (Basel)* **13** (2021). https://doi.org/10.3390/cancers13225596
41 Wang, B. D. *et al.* Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition. *Cell Death Dis* **13**, 272 (2022). https://doi.org/10.1038/s41419-022-04620-3
42 Gasca, J. *et al.* Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer. *Oncotarget* **7**, 52751-52765 (2016). https://doi.org/10.18632/oncotarget.10481
43 Chakravarty, D. *et al.* OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol* **2017** (2017). https://doi.org/10.1200/PO.17.00011
44 National Library of Medicine. *ClinicalTrials.gov*, https://clinicaltrials.gov (2024).
45 Nakamura, K. *et al.* Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer. *JCO Precis Oncol* **4** (2020). https://doi.org/10.1200/PO.19.00368
46 Tung, N. M. *et al.* TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. *J Clin Oncol* **38**, 4274-4282 (2020). https://doi.org/10.1200/JCO.20.02151
47 Gul, A., Leyland-Jones, B., Dey, N. & De, P. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. *Am J Cancer Res* **8**, 2359-2376 (2018).
48 Wang, Q. *et al.* Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. *J Mol Cell Biol* **12**, 125-137 (2020). https://doi.org/10.1093/jmcb/mjz032
49 Drilon, A. *et al.* Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* **383**, 813-824 (2020). https://doi.org/10.1056/NEJMoa2005653
50 Li, H. *et al.* AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells. *Cell Rep Med* **3**, 100554 (2022). https://doi.org/10.1016/j.xcrm.2022.100554
51 Sosinsky, A. *et al.* Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. *Nat Med* **30**, 279-289 (2024). https://doi.org/10.1038/s41591-023-02682-0
52 Davies, H. *et al.* HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. *Nat Med* **23**, 517-525 (2017). https://doi.org/10.1038/nm.4292
53 Genomics Data Commons Data Portal. *National Cancer Institute GDC Data Portal*, https://portal.gdc.cancer.gov/ (2024).
54 Kim, S. *et al.* Strelka2: fast and accurate calling of germline and somatic variants. *Nat Methods* **15**, 591-594 (2018). https://doi.org/10.1038/s41592-018-0051-x
55 Chen, X. *et al.* Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. *Bioinformatics* **32**, 1220-1222 (2016). https://doi.org/10.1093/bioinformatics/btv710

56 Roller, E., Ivakhno, S., Lee, S., Royce, T. & Tanner, S. Canvas: versatile and scalable detection of copy number variants. *Bioinformatics* **32**, 2375-2377 (2016). https://doi.org/10.1093/bioinformatics/btw163
57 Genomics England Research Consortium. *AggV2 ancestry inference*, https://re-docs.genomicsengland.co.uk/ancestry_inference/ (2024).
58 Nassar, A. H. *et al.* Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. *Cancer Cell* **40**, 1161-1172 e1165 (2022). https://doi.org/10.1016/j.ccell.2022.08.022
59 Chen, S. *et al.* A genome-wide mutational constraint map quantified from variation in 76,156 human genomes. *bioRxiv*, 2022.2003.2020.485034 (2022). https://doi.org/10.1101/2022.03.20.485034
60 Tate, J. G. *et al.* COSMIC: the Catalogue Of Somatic Mutations In Cancer. *Nucleic Acids Res* **47**, D941-D947 (2019). https://doi.org/10.1093/nar/gky1015
61 Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290-299 (2021). https://doi.org/10.1038/s41586-021-03205-y
62 Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. *Genome Res* **28**, 1747-1756 (2018). https://doi.org/10.1101/gr.239244.118
63 Krainc, T. & Fuentes, A. Genetic ancestry in precision medicine is reshaping the race debate. *Proc Natl Acad Sci U S A* **119**, e2203033119 (2022). https://doi.org/10.1073/pnas.2203033119
64 Lee, K. K. *et al.* Association of Genetic Ancestry and Molecular Signatures with Cancer Survival Disparities: A Pan-Cancer Analysis. *Cancer Res* **82**, 1222-1233 (2022). https://doi.org/10.1158/0008-5472.CAN-21-2105
65 Ansari-Pour, N. *et al.* Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. *Nat Commun* **12**, 6946 (2021). https://doi.org/10.1038/s41467-021-27079-w
66 Prakash, O. *et al.* Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. *Front Public Health* **8**, 576964 (2020). https://doi.org/10.3389/fpubh.2020.576964
67 Moore, J. X., Andrzejak, S. E., Bevel, M. S., Jones, S. R. & Tingen, M. S. Exploring racial disparities on the association between allostatic load and cancer mortality: A retrospective cohort analysis of NHANES, 1988 through 2019. *SSM Popul Health* **19**, 101185 (2022). https://doi.org/10.1016/j.ssmph.2022.101185
68 Obeng-Gyasi, S. *et al.* Association of Allostatic Load With All-Cause Mortality in Patients With Breast Cancer. *JAMA Netw Open* **6**, e2313989 (2023). https://doi.org/10.1001/jamanetworkopen.2023.13989
69 Miller, A. B. Final results of the UK Age trial on breast cancer screening age. *Lancet Oncol* **21**, 1125-1126 (2020). https://doi.org/10.1016/S1470-2045(20)30428-9
70 Duffy, S. W. *et al.* Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. *Lancet Oncol* **21**, 1165-1172 (2020). https://doi.org/10.1016/S1470-2045(20)30398-3
71 Moser, K. *et al.* Extending the age range for breast screening in England: pilot study to assess the feasibility and acceptability of randomization. *J Med Screen* **18**, 96-102 (2011). https://doi.org/10.1258/jms.2011.011065
72 Newsome, M. We Must Improve Equity in Cancer Screening. *Nature* (2021). https://doi.org/10.1038/d41586-021-03403-8
73 Chen, T., Kharazmi, E. & Fallah, M. Race and Ethnicity-Adjusted Age Recommendation for Initiating Breast Cancer Screening. *JAMA Netw Open* **6**, e238893 (2023). https://doi.org/10.1001/jamanetworkopen.2023.8893

74 Brawley, O. W. *et al.* Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non-Small-Cell Lung Cancer. *JCO Glob Oncol* **7**, 1537-1546 (2021). https://doi.org/10.1200/GO.21.00309
75 Carson, K. R. *et al.* in *ASCO Annual Meeting* Vol. 40 (2022).
76 De La Vega, F., Rhead, B., Pouliot, Y. & Guinney, J. in *ASCO Annual Meeting* Vol. 40 (2022).
77 Valero, C. *et al.* The association between tumor mutational burden and prognosis is dependent on treatment context. *Nat Genet* **53**, 11-15 (2021). https://doi.org/10.1038/s41588-020-00752-4
78 Riviere, P. *et al.* High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers. *Mol Cancer Ther* **19**, 2139-2145 (2020). https://doi.org/10.1158/1535-7163.MCT-20-0161
79 Alva, A. S. *et al.* Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *J Clin Oncol* **39**, 2443-2451 (2021). https://doi.org/10.1200/JCO.20.02923
80 Marabelle, A. *et al.* Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* **21**, 1353-1365 (2020). https://doi.org/10.1016/S1470-2045(20)30445-9
81 Pitt, J. J. *et al.* Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. *Nat Commun* **9**, 4181 (2018). https://doi.org/10.1038/s41467-018-06616-0
82 Bruno, L. *et al.* Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. *JCO Precis Oncol* **6**, e2100140 (2022). https://doi.org/10.1200/PO.21.00140
83 Collins, J. M. *et al.* A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status. *Oncol Ther* **9**, 575-589 (2021). https://doi.org/10.1007/s40487-021-00162-4
84 Balmana, J., Diez, O., Rubio, I. T., Cardoso, F. & Group, E. G. W. BRCA in breast cancer: ESMO Clinical Practice Guidelines. *Ann Oncol* **22 Suppl 6**, vi31-34 (2011). https://doi.org/10.1093/annonc/mdr373
85 Liu, L. *et al.* BRCAness as a prognostic indicator in patients with early breast cancer. *Sci Rep* **10**, 21173 (2020). https://doi.org/10.1038/s41598-020-78016-8
86 Bhaskaran, S. P. *et al.* Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients. *Int J Cancer* **145**, 962-973 (2019). https://doi.org/10.1002/ijc.32176
87 Wang, S. *et al.* Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. *Int J Cancer* **145**, 3321-3333 (2019). https://doi.org/10.1002/ijc.32498
88 Lakeman, I. M. M. *et al.* The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genet Med* **23**, 1726-1737 (2021). https://doi.org/10.1038/s41436-021-01198-7
89 Bhaskaran, S. P. *et al.* Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations. *J Med Genet* **58**, 752-759 (2021). https://doi.org/10.1136/jmedgenet-2020-107299
90 Cancer Research UK and National Institutes of Health. *Cancer Inequities*, https://cancergrandchallenges.org/challenges/cancer-inequities (2024).